Tetraspanins stimulate protein synthesis in myeloma cell lines

Journal of Cellular Biochemistry

Volumn 113, Issue 7, 2012, Pages 2500-2510

  Zismanov, Victoria ^a,b   Drucker, Liat ^a,b   Attar Schneider, Oshrat ^a,b   Matalon, Shelly Tartakover ^a,b   Pasmanik Chor, Metsada ^b   Lishner, Michael ^a,b  

^a MEIR MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

AMPK; Multiple myeloma; protein synthesis; ribosome; rps6; snornas; tetraspanins

Indexed keywords

IMMUNOGLOBULIN; MAMMALIAN TARGET OF RAPAMYCIN; SYNAPTOPHYSIN; TETRASPANIN;

ARTICLE; CELL DEATH; CELL NUCLEUS; CELL STRUCTURE; MICROARRAY ANALYSIS; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN SYNTHESIS;

AMP-ACTIVATED PROTEIN KINASES; ANTIGENS, CD81; ANTIGENS, CD82; APOPTOSIS; CELL LINE, TUMOR; HUMANS; IMMUNOGLOBULINS; MULTIPLE MYELOMA; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN BIOSYNTHESIS; RIBOSOMAL PROTEIN S6; TETRASPANINS; TOR SERINE-THREONINE KINASES;

EID: 84861041077     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.24126     Document Type: Article

References (50)

1. Agnelli L, Fabris S, Bicciato S, Basso D, Baldini L, Morabito F, Verdelli D, Todoerti K, Lambertenghi-Deliliers G, Lombardi L, Neri A,. 2007. Upregulation of translational machinery and distinct genetic subgroups characterise hyperdiploidy in multiple myeloma. Br J Haematol 136: 565-573.
2. Anderson K,. 2007. Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions. Exp Hematol 35: 155-162.
3. Asnaghi L, Bruno P, Priulla M, Nicolin A,. 2004. mTOR: A protein kinase switching between life and death. Pharmacol Res 50: 545-549.
4. Barnhart B, Simon M,. 2007. Taking aim at translation for tumor therapy. J Clin Invest 117: 2385-2388.
5. Baserga R,. 2007. Is cell size important ? Cell Cycle 6: 814-816.
6. Bergsagel PL, Kuehl WM,. 2005. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 23: 6333-6338.
7. Borset M, Hjertner O, Yaccoby S, Epstein J, Sanderson RD,. 2000. Syndecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparin-binding proteins. Blood 96: 2528-2536.
8. Cargnello M, Roux PP,. 2011. Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases. Microbiol Mol Biol Rev 75: 50-83.
9. Carrasco D, Sukhdeo K, Protopopova M, Sinha R, Enos M, Carrasco D, Zheng M, Mani M, Henderson J, Pinkus G, Munshi N, Horner J, Ivanova E, Protopopov A, Anderson K, Tonon G, DePinho R,. 2007. The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell 11: 349-360.
10. Cenci S, Sitia R,. 2007. Managing and exploiting stress in the antibody factory. FEBS Lett 581: 3652-3657.
11. Cheyssac C, Dina C, Lepretre F, Vasseur-Delannoy V, Dechaume A, Lobbens S, Balkau B, Ruiz J, Charpentier G, Pattou F, Joly E, Prentki M, Hansen T, Pedersen O, Vaxillaire M, Froguel P,. 2006. EIF4A2 is a positional candidate gene at the 3q27 locus linked to type 2 diabetes in French families. Diabetes 55: 1171-1176.
12. Cuenda A, Rousseau S,. 2007. p38 MAP-kinases pathway regulation, function and role in human diseases. Biochim Biophys Acta 1773: 1358-1375.
13. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB,. 2008. The biology of cancer: Metabolic reprogramming fuels cell growth and proliferation. Cell Metab 7: 11-20.
14. Dezorella N, Pevsner-Fischer M, Deutsch V, Kay S, Baron S, Stern R, Tavor S, Nagler A, Naparstek E, Zipori D, Katz BZ,. 2009. Mesenchymal stromal cells revert multiple myeloma cells to less differentiated phenotype by the combined activities of adhesive interactions and interleukin-6. Exp Cell Res 315: 1904-1913.
15. Drucker L, Tohami T, Tartakover-Matalon S, Zismanov V, Shapiro H, Radnay J, Lishner M,. 2006. Promoter hypermethylation of tetraspanin members contributes to their silencing in myeloma cell lines. Carcinogenesis 27: 197-204.
16. Fogarty S, Hardie DG,. 2010. Development of protein kinase activators: AMPK as a target in metabolic disorders and cancer. Biochim Biophys Acta 1804: 581-591.
17. Frey MR, Wu W, Dunn JM, Matera AG,. 1997. The U22 host gene (UHG): Chromosomal localization of UHG and distribution of U22 small nucleolar RNA. Histochem Cell Biol 108: 365-370.
18. Gee HE, Buffa FM, Camps C, Ramachandran A, Leek R, Taylor M, Patil M, Sheldon H, Betts G, Homer J, West C, Ragoussis J, Harris AL,. 2011. The small-nucleolar RNAs commonly used for microRNA normalisation correlate with tumour pathology and prognosis. Br J Cancer 104: 1168-1177.
19. Ginion A, Auquier J, Benton CR, Mouton C, Vanoverschelde JL, Hue L, Horman S, Beauloye C, Bertrand L,. 2011. Inhibition of the mTOR/p70S6K pathway is not involved in the insulin-sensitizing effect of AMPK on cardiac glucose uptake. Am J Physiol Heart Circ Physiol 301: H469-H477.
20. Grigsby IF, Pham L, Gopalakrishnan R, Mansky LM, Mansky KC,. 2010. Downregulation of Gnas, Got2 and Snord32a following tenofovir exposure of primary osteoclasts. Biochem Biophys Res Commun 391: 1324-1329.
21. Han S, Khuri FR, Roman J,. 2006. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways. Cancer Res 66: 315-323.
22. Hasegawa M, Furuya M, Kasuya Y, Nishiyama M, Sugiura T, Nikaido T, Momota Y, Ichinose M, Kimura S,. 2007. CD151 dynamics in carcinoma-stroma interaction: Integrin expression, adhesion strength and proteolytic activity. Lab Invest 87: 882-892.
23. Hutchinson JA, Shanware NP, Chang H, Tibbetts RS,. 2011. Regulation of ribosomal protein S6 phosphorylation by casein kinase 1 and protein phosphatase 1. J Biol Chem 286: 8688-8696.
24. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP,. 2003. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4: 249-264.
25. Kalender A, Selvaraj A, Thomas G,. 2011. A matter of energy stress: p38beta meets mTORC1. Cell Res 21: 859-861.
26. Kawauchi K, Ogasawara T, Yasuyama M, Otsuka K, Yamada O,. 2009. The PI3K/Akt pathway as a target in the treatment of hematologic malignancies. Anticancer Agents Med Chem 9: 550-559.
27. Kiss AM, Jady BE, Bertrand E, Kiss T,. 2004. Human box H/ACA pseudouridylation guide RNA machinery. Mol Cell Biol 24: 5797-5807.
28. Lazo PA,. 2007. Functional implications of tetraspanin proteins in cancer biology. Cancer Sci 98: 1666-1677.
29. Liao J, Yu L, Mei Y, Guarnera M, Shen J, Li R, Liu Z, Jiang F,. 2010. Small nucleolar RNA signatures as biomarkers for non-small-cell lung cancer. Mol Cancer 9: 198.
30. Lishner M, Zismanov V, Tohami T, Tartakover-Matalon S, Elis A, Drucker L,. 2008. Tetraspanins affect myeloma cell fate via Akt signaling and FoxO activation. Cell Signal 20: 2309-2316.
31. Maecker HT,. 2003. Human CD81 directly enhances Th1 and Th2 cell activation, but preferentially induces proliferation of Th2 cells upon long-term stimulation. BMC Immunol 4: 1.
32. Manthey CL, Wang SW, Kinney SD, Yao Z,. 1998. SB202190, a selective inhibitor of p38 mitogen-activated protein kinase, is a powerful regulator of LPS-induced mRNAs in monocytes. J Leukoc Biol 64: 409-417.
33. Matera AG, Terns RM, Terns MP,. 2007. Non-coding RNAs: Lessons from the small nuclear and small nucleolar RNAs. Nat Rev Mol Cell Biol 8: 209-220.
34. Meister S, Schubert U, Neubert K, Herrmann K, Burger R, Gramatzki M, Hahn S, Schreiber S, Wilhelm S, Herrmann M, Jack HM, Voll RE,. 2007. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition. Cancer Res 67: 1783-1792.
35. Meyuhas O,. 2008. Physiological roles of ribosomal protein S6: One of its kind. Int Rev Cell Mol Biol 268: 1-37.
36. Ng TL, Leprivier G, Robertson MD, Chow C, Martin MJ, Laderoute KR, Davicioni E, Triche TJ, Sorensen PH,. 2011. The AMPK stress response pathway mediates anoikis resistance through inhibition of mTOR and suppression of protein synthesis. Cell Death Differ 19: 501-510.
37. Powers ET, Morimoto RI, Dillin A, Kelly JW, Balch WE,. 2009. Biological and chemical approaches to diseases of proteostasis deficiency. Annu Rev Biochem 78: 959-991.
38. Ravitz M, Chen L, Lynch M, Schmidt E,. 2007. c-Myc repression of TSC2 contributes to control of translation initiation and Myc-induced transformation. Cancer Res 67: 11209-11217.
39. Saha AK, Xu XJ, Lawson E, Deoliveira R, Brandon AE, Kraegen EW, Ruderman NB,. 2010. Downregulation of AMPK accompanies leucine- and glucose-induced increases in protein synthesis and insulin resistance in rat skeletal muscle. Diabetes 59: 2426-2434.
40. Saito Y, Tachibana I, Takeda Y, Yamane H, He P, Suzuki M, Minami S, Kijima T, Yoshida M, Kumagai T, Osaki T, Kawase I,. 2006. Absence of CD9 enhances adhesion-dependent morphologic differentiation, survival, and matrix metalloproteinase-2 production in small cell lung cancer cells. Cancer Res 66: 9557-9565.
41. Shaffer AL, Shapiro-Shelef M, Iwakoshi NN, Lee AH, Qian SB, Zhao H, Yu X, Yang L, Tan BK, Rosenwald A, Hurt EM, Petroulakis E, Sonenberg N, Yewdell JW, Calame K, Glimcher LH, Staudt LM,. 2004. XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation. Immunity 21: 81-93.
42. Sharan R, Maron-Katz A, Shamir R,. 2003. CLICK and EXPANDER: A system for clustering and visualizing gene expression data. Bioinformatics 19: 1787-1799.
43. Su DF, Xu LP, Miao CY, Xie HH, Shen FM, Jiang YY,. 2004. Two useful methods for evaluating antihypertensive drugs in conscious freely moving rats. Acta Pharmacol Sin 25: 148-151.
44. Tafer H, Kehr S, Hertel J, Hofacker IL, Stadler PF,. 2010. RNAsnoop: Efficient target prediction for H/ACA snoRNAs. Bioinformatics 26: 610-616.
45. Tohami T, Drucker L, Radnay J, Shapira H, Lishner M,. 2004. Expression of tetraspanins in peripheral blood leukocytes: A comparison between normal and infectious conditions. Tissue Antigens 64: 235-242.
46. Tohami T, Drucker L, Shapiro H, Radnay J, Lishner M,. 2007. Overexpression of tetraspanins affects multiple myeloma cell survival and invasive potential. FASEB J 21: 691-699.
47. Tycowski KT, Shu MD, Steitz JA,. 1996. A mammalian gene with introns instead of exons generating stable RNA products. Nature 379: 464-466.
48. Viollet B, Horman S, Leclerc J, Lantier L, Foretz M, Billaud M, Giri S, Andreelli F,. 2010. AMPK inhibition in health and disease. Crit Rev Biochem Mol Biol 45: 276-295.
49. Yamasaki S, Anderson P,. 2008. Reprogramming mRNA translation during stress. Curr Opin Cell Biol 20: 222-226.
50. Zismanov V, Lishner M, Tartakover-Matalon S, Radnay J, Shapiro H, Drucker L,. 2009. Tetraspanin-induced death of myeloma cell lines is autophagic and involves increased UPR signalling. Br J Cancer 101: 1402-1409.